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Abstract
Stem cells are thought to be the cell of origin in malignant transformation in many tissues, but their role in human prostate
carcinogenesis continues to be debated. One of the conflicts with this model is that cancer stem cells have been described
to lack androgen receptor (AR) expression, which is of established importance in prostate cancer initiation and progression.
We re-examined the expression patterns of AR within adult prostate epithelial differentiation using an optimised sensitive
and specific approach examining transcript, protein and AR regulated gene expression. Highly enriched populations were
isolated consisting of stem (a2b1
HI CD133+VE), transiently amplifying (a2b1
HI CD133–VE) and terminally differentiated (a2b1
LOW
CD133–VE) cells. AR transcript and protein expression was confirmed in a2b1
HI CD133+VE and CD133–VE progenitor cells. Flow
cytometry confirmed that median (6SD) fraction of cells expressing AR were 77% (66%) in a2b1
HI CD133+VE stem cells and
68% (612%) in a2b1
HI CD133–VE transiently amplifying cells. However, 3-fold lower levels of total AR protein expression
(peak and median immunofluorescence) were present in a2b1
HI CD133+VE stem cells compared with differentiated cells. This
finding was confirmed with dual immunostaining of prostate sections for AR and CD133, which again demonstrated low
levels of AR within basal CD133+VE cells. Activity of the AR was confirmed in prostate progenitor cells by the expression of
low levels of the AR regulated genes PSA, KLK2 and TMPRSS2. The confirmation of AR expression in prostate progenitor cells
allows integration of the cancer stem cell theory with the established models of prostate cancer initiation based on a
functional AR. Further study of specific AR functions in prostate stem and differentiated cells may highlight novel
mechanisms of prostate homeostasis and insights into tumourigenesis.
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Introduction
Androgen signalling has been shown to be integral to prostate
cancer development as it can induce and regulate TMPRSS2–ERG
gene fusions, which initiate malignant transformation and drive
disease progression [1–3]. Even without this fusion, AR signalling
remains central to prostate carcinogenesis [4–6].
There is increasing evidence that stem cells are the targets for
tumourigenesis due to their inherent self-renewal capability, anti-
apoptotic pathways and maintenance throughout the lifetime of an
individual granting time for mutations to accumulate. Human
studies of tumourigenesis in xenografts have demonstrated the
importance of AR signalling in disease initiation in the basal layer
of prostate epithelium [6]. In mice, evidence is growing that there
are both basal and luminal stem cells and debate remains over
where the critical tumourigenic mutations occur, nevertheless both
these models of carcinogenesis required an active AR [7–11]. In
the human setting, a common clonal origin has been confirmed for
basal, luminal and neuroendocrine cells [12,13]. Human prostate
stem cells can be enriched by their gene signature of a2b1
HI and
glycosylated CD133 expression, transiently amplifying cells are
characterised by a2b1
HI CD133–VE expression and terminally
differentiated cells are defined by the marker a2b1
LOW CD133–VE
[14–17]. Both stem cells and cancer stem cells described by these
signatures from primary human prostates have typically lacked AR
expression [14,18]. The existence of AR–VE cancer stem cells has
been postulated as a mechanism by which tumours relapse by
overcoming androgen ablative therapies that target AR+VE cells
[18]. However, it is established that the AR remains active and
even amplified in castration resistant prostate cancer (CRPC) [19–
21]. If the prostate stem cell is the cell of origin for transformation,
then this model appears to be at odds with the emerging
mechanisms of prostate cancer development and progression
dependent upon AR signalling. In this work, we focus on re-
examining the expression profiles of AR in prostate epithelial
differentiation and challenge the dogma that prostate stem cells
lack AR.
Methods
Tissue Collection and Isolation of Epithelial Cells
Human prostate samples were obtained from 20 patients
following transurethral resection of the prostate for benign
prostatic hyperplasia or cystoprostatectomy for bladder cancer.
Pathologist assessment confirmed benign histology and the
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samples underwent processing and selection as previously
described [14–16]: Magnetic activated cell sorting (MACS) was
performed for immunomagnetic selection of Epithelial Cell
Adhesion Molecule (EpCAM/CD326) (Miltenyi Biotec, Woking,
UK). Epithelial a2b1
HI (stem and transiently amplifying cells) and
a2b1
LOW (differentiated) cells were selected by rapid adhesion to
collagen-1. Epithelial a2b1
HI CD133+VE cells were separated by
either CD133 immunomagnetic selection (CD133/1, Miltenyi
Biotec) or FACS (CD133/2, Miltenyi Biotec). In our work,
selected primary samples were never cultured prior to experimen-
tation to avoid adaptations of cells in an in vitro environment and
subsequent deviation of their phenotypes [22–24].
Maintenance of Prostate Cancer Cell Lines
The human prostate cancer cell lines LNCaP (AR+VE) and PC3
(AR–VE) (American Type Culture Collection) were maintained in
RPMI1640 medium (Sigma, Dorset, UK) containing 10% foetal
calf serum and 2 mM L-glutamine.
siRNA Knockdown of AR
Cells were seeded in six well plates prior to being transfected
with either small interfering RNA (siRNA) (Sense strand 59
CCAUCUUUCUGAAUGUCCU dTdT 39, antisense 59 AGGA-
CAUUCAGAAAGAUGG dTdT 39) for AR or non-silencing
siRNA (Sense strand 59 UUCUCCGAACGUGUCACGU dTdT
39, antisense 59 ACGUGACACGUUCGGAGAA dTdT 39) using
LipofectamineTM RNAiMAX (Invitrogen, Paisley, UK).
Quantitative Real Time PCR Analysis
Prostate epithelia was separated into three distinct fractions,
a2b1
HI CD133+VE stem cells, a2b1
HI CD133–VE transiently
amplifying cells and a2b1
LOW CD133–VE terminally differentiated
cells and underwent RNA isolation (micro RNeasy, Qiagen,
Crawley, UK). Message BOOSTERTM cDNA synthesis amplifi-
cation kit (Epicentre Biotechnologies, Madison, WI, USA) was
employed and real-time PCR (Applied Biosystems 7900HT) was
performed using SYBR green (Invitrogen) using the following
specific primer sets: AR (forward 59-CTG GAC ACG ACA ACA
ACC AG-39, reverse 59-CAG ATC AGG GGC GAA GTA GA-
39), PSA (forward 59-CAA TGA CGT GTG TGC GCA A-39,
reverse 59-CGT GAT ACC TTG AAG CAC ACC A-39), KLK2
(forward 59-AGC ATC GAA CCA GAG GAG TTC T-39, reverse
59-TGG AGG CTC ACA CAC TGA AGA-39), TMPRSS2
(forward 59-CTG CTG GAT TTC CGG GTG-39, reverse 59-
TTC TGA GGT CTT CCC TTT CTC CT-39), CD24 (forward
59-TGA AGA ACA TGT GAG AGG TTT GAC-39, reverse 59-
GAA AAC TGA ATC TCC ATT CCA CAA-39), CD146
(forward 59-CCA TTT TTG GCC CCC CT-39, reverse 59TCA
CCC ACA CCT TCC TCT CCT-39) and CD45 (forward 59-
GAA ATT GTT CCT CGT CTG AT-39, reverse 59-CTT TGC
CCT GTC ACA AAT AC-39) before being normalised to
GAPDH (forward 59-CGA CCA CTT TGT CAA GCT CA-39,
reverse 59-GGG TCT TCC TTG GAG GC-39).
Flow Cytometry
Cells were fixed with Fixation/Permeabilisation solution (BD
Bioscience, Oxford, UK) before incubation in methanol at
220uC for 16 hours to permeabilise the nucleus. Cells were
labelled with anti-AR antibody (PG-21, Millipore) and second-
ary FITC (Dako, Ely, UK), and CD133/2 antibody directly
conjugated to PE (Miltenyi Biotec). Controls included IgG
isotype antibody (Dako) and PE conjugated isotype antibody
(Miltenyi Biotec). When required, cells were counterstained with
the nuclear stain DRAQ5TM (Biostatus, Shepshed, UK)
according to the manufacturer’s recommendations. Samples
were analysed using either a FACS Calibur flow cytometer (BD
Biosciences) or ImageStreamX Mark II cytometer (Amnis,
Ipswich, UK).
Western Blot Analysis
Resolved lysates (12% polyacrylamide gel) were transferred to
Hybond C membranes (Amersham Biosciences, Amersham, UK)
and probed with either 1:1000 AR (G122-434, BD Pharmingen),
or 1:4000 a-tubulin (T9026, Sigma) antibodies, followed by 1:500
rabbit anti-mouse HRP secondary antibody (DAKO) for subse-
quent visualization using the ECL detection system (GE
Healthcare, Little Chalfont, UK).
Sequential Alkaline Phosphatase Immunostaining
CD133/AR dual staining was carried out on prostate sections
using methodologies previously described [25]. Briefly, sections
were stained with CD133/1 antibody (Miltenyi Biotec) according
to manufacturer’s recommendations prior to detection using Poly-
AP-GAM/R/R Immunoglobulins (Immunologic, Duiven, The
Netherlands) and visualised with Alkaline phosphatase substrate kit
III (SK-5300, Vector labs, Burligame, Ca, USA). Sections were
cleared of antibodies with a second antigen retrieval before
staining for AR (SC-816, Santa Cruz), detection with Poly-AP-
GAM/R/R Immunoglobulins and visualisation with Alkaline
phosphatase substrate kit I (SK-5100, Vector labs) and mounting
slides in Vecta Mount (H-5000, Vector labs).
Results
The Purity of Human EpCaM+VE a2b1
HI CD133+VE Prostate
Cell Selections was Confirmed
It is established that primary culture results in changes in
phenotype from those seen in vivo [23,24,26] and of particular
relevance, studies in glioma have demonstrated that CD133
expression is altered as a result of in vitro conditions [27].
Therefore, in our studies no culturing of samples was carried
out prior to experimentation. However, this approach can lead
to a greater chance of contamination by unwanted cell lineages,
such as blood or stroma cell types, and a previously optimised
protocol for epithelial extraction was employed (Figure 1A) [14–
16,28,29]. Lineage-specific markers for epithelial (CD24),
endothelial (CD146) and haematopoietic (CD45) cells were
assessed and the purity of epithelial cell enrichment was
confirmed by real time PCR, confirming depletion of unwanted
cell lineages with this method (Figure 1B). In order to assess the
enrichment of glycosylated CD133, cells were dual-stained for
CD133/1 immunomagnetic beads and an anti-CD133/2
antibody that targets an epitope distinct from CD133/1. Flow
cytometry data showed that in the prostate CD133/1 and
CD133/2 are exclusively co-expressed, confirming .98% purity
in glycosylated-CD133+VE cells (Figure 1C). Similarly using real
time PCR, immunomagnetic selection for glycosylated-CD133
resulted in enrichment for cells expressing high levels of CD133
mRNA and depleted CD133 expression in the negative
fractions (Figure 1D).
The Sensitivity and Specificity of AR Detection by Flow
Cytometry was Validated
In order to accurately determine the presence of the AR in rare
cell types within the prostate, a flow cytometry approach was
developed, allowing both sensitive and specific quantification.
Androgen Receptor in Human Prostate Stem Cells
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Using a specific AR antibody (PG-21, Millipore), an optimised
staining protocol was developed using prostate cancer cell lines
LNCaP (AR+VE) and PC3 (AR–VE), allowing identification of the
highest concentrations of antibody to increase sensitivity whilst
controlling for non-specific labelling (Figure 2A). Specific AR
expression was confirmed by comparison to an IgG-specific
isotype control in conjunction with the AR–VE cell line PC3
(Figure 2B). Specificity of this staining was further confirmed in
Figure 1. Strategy of enrichment for required cell types. A) Schematic work flow for enrichment of epithelial cells for assessment of AR
expression. B) Purity of selection by expression of the lineage specific markers CD24 (epithelial), CD146 (endothelial) and CD45 (haematopoietic)
normalised to GAPDH following real-time PCR for unsorted prostate epithelia and EpCAM/HEA sorted epithelia, error bars represent standard error of
the mean for n = 3. C) CD133/1 Sorted samples were assessed for purity by co-expression of the CD133/2 epitope, confirming that these two epitopes
are co-expressed in the prostate and that our CD133 selection efficiently enriches for CD133+VE cells: Upper dotplot representative of CD133/2
staining for unsorted a2b1
HI epithelial cells; lower left dotplot representative of CD133/2 staining for a2b1
HI CD133/1–VE cells; lower right dotplot
representative of CD133/2 staining for a2b1
HI CD133/1+VE cells. Gates are set according to appropriate isotype controls. D) Confirmation of CD133
enrichment with real-time PCR. CD133 expression is shown normalised to GAPDH, error bars represent standard error of the mean n= 10.
doi:10.1371/journal.pone.0048944.g001
Androgen Receptor in Human Prostate Stem Cells
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LNCaP following siRNA knockdown of the AR using flow
cytometry (Figure 2C and 2D). Western Blot analysis was also
employed to confirm the specificity of the AR knockdown with
siRNA, which correlated directly with the flow cytometry result
(Figure 2E).
Androgen Receptor was Detected at Low Levels in
Prostate Stem Cell Enriched Cells
AR transcript levels were examined in a2b1
HI CD133+VE,
a2b1
HI CD133–VE and a2b1
LOW CD133–VE cells and were
detectable at every stage of differentiation from stem cells through
Figure 2. Validation of AR detection with flow cytometry. A) Percentage of cells staining above a no antibody control for either isotype
antibody (hollow points) or PG-21 AR antibody (solid points) in LNCaP (circles) or PC3 (triangles) across a dilution series. B) Representative staining
patterns for PC3 (upper dotplots) and LNCaP (lower dotplots) for either 1:200 isotype antibody (left dotplots) or 1:200 PG-21 AR antibody (right
dotplots) of equivalent concentrations. Gates set according to isotype control. C) Left dotplot representative of staining of LNCaP with isotype
control, right dotplots representative of AR staining in non-transfected LNCaP (upper), LNCaP transfected with scrambled siRNA (middle dotplot) and
LNCaP transfected with AR siRNA (lower). Gates were set according to an appropriate isotype control. D) Percentage of cells staining positive for AR
relative to an isotype control in non-transfected LNCaP, LNCaP transfected with scrambled siRNA and LNCaP transfected with AR siRNA. Error bars
represent standard error of the mean for n = 3. E)Western blots of AR expression for non-transfected LNCaP, LNCaP transfected with scrambled siRNA
and LNCaP transfected with AR siRNA are shown using a different AR antibody (G122-434, BD Pharmingen).
doi:10.1371/journal.pone.0048944.g002
Androgen Receptor in Human Prostate Stem Cells
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Figure 3. Expression of the AR within the prostate epithelial hierarchy of differentiation. Error bars represent standard error of the mean.
A) Expression of AR transcript relative to GAPDH. Error bars represent standard error of the mean for n = 10. B) Upper dotplot representative of
CD133 staining for progenitor a2b1
HI cells. Lower left dotplot representative of AR expression in CD133–VE gated a2b1
HI cells. Lower right dotplot
representative of AR expression in CD133+VE gated a2b1
HI cells. Gates were set according to appropriate isotype controls. C) Mean percentage of cells
expressing the AR in CD133+VE and CD133–VE a2b1
HI cells (n = 6). D) Representative histograms for fluorescence of a2b1
HI and a2b1
LOW isotype controls
and AR detection. E) Mean fold change in median staining relative to isotype control for AR stained a2b1
HI cells and a2b1
LOW cells (n = 6).
doi:10.1371/journal.pone.0048944.g003
Androgen Receptor in Human Prostate Stem Cells
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to terminally differentiated cells from each patient sample
examined (n = 10) (Figure 3A). Flow cytometry confirmed that
similar proportion of CD133+VE stem cell enriched cells and
CD133–VE transiently amplifying cells expressed AR protein
(Figure 3B), with the mean (6SD) fraction of cells stained positive
for AR being 77% (66%) in a2b1
HI CD133+VE cells and 68%
(612%) in a2b1
HI CD133–VE cells (Figure 3C). Primary progenitor
enriched a2b1
HI cells (CD133+VE stem and CD133–VE transiently
amplifying cells) demonstrated a clear population shift in
fluorescence intensity on the histogram from flow cytometry
compared to the isotype control when stained with AR (Figure 3D).
In particular, the primary a2b1
HI cells showed 2.54 (SD=60.50)
fold increase in the median and 2.45 fold (SD=60.31) in the peak
fluorescence compared to their isotype controls, whereas a2b1
LOW
terminally differentiated cells, showed an increase by 8.69
(SD=61.54) fold for the median and 6.80 (SD=61.11) fold for
the peak fluorescence compared to their isotype controls
(Figure 3E). In particular, the a2b1
HI progenitor cells did not
stain as intensely (3-fold lower) as terminally differentiated prostate
epithelial cells (p,0.005) (Figure 3E).
To confirm this result, samples were analysed with the
ImageStreamX Mark II cytometer, which combines flow cytom-
etery with fluorescent microscopy, allowing visualisation of rare
cell events within a sample. AR was once again confirmed to be
expressed by a2b1
HI CD133+VE and a2b1
HI CD133–VE cells with
higher immunofluorescence expression seen within a2b1
LOW
CD133–VE cells (Figure 4A). By counterstaining cells with
DRAQ5TM, AR localisation could be estimated within the cells
in suspension. All three fractions showed AR expression overlaying
with the nucleus, suggesting the AR is active throughout prostate
differentiation. In order to establish if the AR was functionally
active in the rare prostate progenitor cells, expression of androgen
regulated genes was examined (Figure 4B). Expression of PSA,
KLK2 and TMPRSS2 was confirmed at all stages of prostate
differentiation, including activity in the a2b1
HI CD133+VE stem
cell enriched cells. Corresponding with the expected increased
expression of AR in differentiation, a marked increase in the AR
Figure 4. AR expression and activity within the prostate epithelial hierarchy of differentiation. A) Representative images of expression of
CD133 and AR counterstained with DRAQ5TM within prostate EpCAM+VE a2b1
HI CD133+VE (Left panel), a2b1
HI CD133–VE (central panel) and a2b1
LOW
CD133–VE cells (right panel). B) Expression of the AR regulated genes PSA, KLK2 and TMPRSS2 normalised to GAPDH (n= 10) (p,0.001 comparing
a2b1
HI and a2b1
LOW). Error bars represent standard error of the mean.
doi:10.1371/journal.pone.0048944.g004
Androgen Receptor in Human Prostate Stem Cells
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function was demonstrated when comparing the stem fraction to
the differentiated fraction: PSA mean fold change= 36.8
(SD=615.1), KLK2 mean fold change= 4.3 (SD=61.5) and
TMPRSS2 mean fold change = 2.3 (SD=60.5).
Distribution of the Androgen Receptor and Prostate
Stem Cells within the Human Prostate Epithelium
To evaluate the expression of AR and CD133 within normal
prostate histology, dual alkaline phosphatase staining was
employed. Using an optimised AR antibody, it was possible to
detect AR within the prostate epithelium in both the luminal layer
in addition to low levels within the basal epithelium (Figure 5A).
Dual staining also allowed the identification of CD133 positive
cells within the prostate epithelium in 2% of sections studied (8/
342 sections), with cells always restricted to the basement
membrane of the epithelium with localised staining of CD133 in
keeping with its expression limited to membrane protrusions with
a characteristic punctate pattern [14,30]. As with the flow
cytometry data, the identified CD133+VE cells also expressed AR
but at a lower level than that seen in luminal cells within the same
gland (Figure 5B).
Discussion
In this study, we established that AR expression is detectable at
low levels in the a2b1
HI CD133+VE stem cell enriched cells of the
prostate, using a combination of PCR, dual staining immunohis-
tochemistry and highly specific and sensitive flow cytometry
methods. Moreover, we confirmed that AR was active in the stem
cell enriched populations by their expression of TMPRSS2, KLK2
and low levels of PSA. However, these expression levels were lower
in comparison to differentiated cells.
Previously, a2b1
HI CD133+VE prostate basal stem cells have
been shown to lack AR expression [14,16], and the discrepancies
between our data and these studies on CD133+VE and AR
expression may be due to the sensitivity and the specificity of the
assay used. In particular, we showed that AR levels were 3-fold
lower than differentiated cells, which potentially accounts for the
difficulties in detecting the AR in extremely rare prostate
progenitor cells using less sensitive approaches such as western
blot [31]. A recent report identified a highly conserved site in the
second intron of the AR gene that regulates its expression in
response to androgen stimulation and withdrawal [32]. Specifi-
cally, it was shown that AR binding to this response element
decreased AR gene expression by functioning as a transcriptional
suppressor at this site and this may be a mechanism to explain
why, despite 3-fold lower levels of AR protein, there were similar
levels of AR transcripts in a2b1
HI CD133+VE stem and differen-
tiated cells. Additional explanation for our findings was that in
contrast to previous studies we did not culture samples prior to
analysis as CD133 expression is altered as a result of in vitro
conditions [27]. In particular, AR protein undergoes rapid
metabolic turnover in prostate cells and ex vivo culture rapidly
leads to low or undetectable levels of AR protein expression
[28,33]. These issues associated with measuring CD133 and AR
may also explain discrepancies between CD133+VE cancer stem
cell studies where both the presence and absence of AR is reported
[18,34]. Having validated AR expression in a2b1
HI CD133+VE
cells, there is a possibility that there are differential AR functions in
prostate stem and differentiated populations [35], particularly
given that progenitor cells are also indirectly responsive to
androgens through paracrine signalling of growth factors from
adjacent AR+VE stroma [28,36,37]. Further work exploring this
possibility would be of interest and may identify new mechanisms
of homeostasis and potential insights into tumourigenesis.
A recent characterisation of prostate stem cells has identified
TRA-1-60/CD151/CD166+VE stem cells which were AR–VE
[38]. These cells may represent an acquired phenotype following
up-regulation of pluripotent markers seen in advanced cancers
[39] that drive de-differentiation [40] into a state more in keeping
with embryogenesis (e.g. TRA-1-60 expression) and lacking
markers of prostate-specific lineage. However, it is accepted that
the TRA-1-60/CD151/CD166+VE stem cell may have arisen
from a cell of origin for cancer that lacks AR, as in our study we
did identify a very small fraction (19%) of a2b1
HI CD133+VE cells
lacking AR expression (0.0002% of the total epithelium [14]). This
Figure 5. CD133 and AR dual immunohistochemistry. Red stain represents AR expression, blue stain represents CD133 expression, black bars
are 50 mm scale bars. A) Representative image of AR staining within prostatic acini. Red arrow identifies basal layer, blue arrow identifies luminal layer.
B) Representative image of CD133 and AR expression in the prostate epithelium, insert shows CD133+VE AR +VE cell within the basal layer.
doi:10.1371/journal.pone.0048944.g005
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may have clinical relevance where individual tumours may have
different cancer stem cell origins, each with their own specific
pathobiology requiring tailoring therapies. Further comparative
studies are needed to resolve differences between the TRA-1-60/
CD151/CD166+VE and the a2b1
HI CD133+VE cancer stem cell
models.
In summary, studies of human prostate cancer have demon-
strated basal cells, within which the a2b1
HI CD133+VE stem cell
resides, are efficient targets of prostate cancer initiation and that
AR expression is required [6,7]. Therefore, the stem cell, which
remains the most likely target for transformation, would be
expected to have AR expression too. As previously human prostate
stem cells were considered to lack AR, the characterisation of AR
expression within a2b1
HI CD133+VE cells offers a resolution to a
key paradox about the cell of origin in prostate cancer. Further
study of specific AR functions in prostate stem and differentiated
cells may highlight novel mechanisms of prostate homeostasis and
insights into tumourigenesis.
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